Free Trial

Kiniksa Pharmaceuticals (KNSA) Earnings Date, Estimates & Call Transcripts

Kiniksa Pharmaceuticals logo
$21.21 +0.39 (+1.87%)
(As of 11/20/2024 ET)

Kiniksa Pharmaceuticals Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 26Estimated
Actual EPS
(Oct. 29)
-$0.18 Missed By -$0.17
Consensus EPS
(Oct. 29)
-$0.01

Kiniksa Pharmaceuticals posted Q3 2024 earnings on October 29, 2024, reporting an EPS of -$0.18, which missed analysts' consensus estimates of -$0.01 by $0.17. Quarterly revenue rose 67.4% year-over-year to $112.21 million, above analysts' expectations of $111.51 million. With a trailing EPS of -$0.14, Kiniksa Pharmaceuticals' earnings are expected to grow next year, from ($0.55) to $0.10 per share.

KNSA Upcoming Earnings

Kiniksa Pharmaceuticals' next earnings date is estimated for Wednesday, February 26, 2025, based off prior year's reporting schedules.

Get Kiniksa Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiniksa Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

KNSA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KNSA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Kiniksa Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.13-$0.13-$0.13
Q2 20241-$0.06-$0.06-$0.06
Q3 20241$0.06$0.06$0.06
Q4 20241$0.06$0.06$0.06
FY 20244-$0.07-$0.07-$0.07
Q1 20251$0.09$0.09$0.09
Q2 20251$0.08$0.08$0.08
Q3 20251$0.13$0.13$0.13
Q4 20251$0.19$0.19$0.19
FY 20254$0.49$0.49$0.49

Kiniksa Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
2/26/2025
(Estimated)
------- 
10/29/2024Q3 2024-$0.01-$0.18 -$0.17-$0.18$111.51M$112.21M        
7/23/2024Q2 2024-$0.09-$0.06+$0.03-$0.06$90.60M$108.30M        
4/23/2024Q1 2024-$0.14-$0.25 -$0.11-$0.25$76.97M$79.90M        
2/28/2024Q4 2023-$0.11$0.04+$0.15-$0.27$72.31M$83.40M    
10/31/2023Q3 2023-$0.18-$0.20 -$0.02-$0.20$62.53M$67.05M    
7/25/2023Q2 2023-$0.16-$0.02+$0.14-$0.25$52.33M$71.47M    
5/2/2023Q1 2023-$0.18-$0.18--$0.18$45.95M$48.35M    
2/28/2023Q4 2022-$0.24$0.06+$0.30$0.06$47.18M$61.88M

Kiniksa Pharmaceuticals Earnings - Frequently Asked Questions

Kiniksa Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates. Learn more on KNSA's earnings history.

In the previous quarter, Kiniksa Pharmaceuticals (NASDAQ:KNSA) missed the analysts' consensus estimate of ($0.01) by $0.17 with a reported earnings per share (EPS) of ($0.18). Learn more on analysts' earnings estimate vs. KNSA's actual earnings.

The conference call for Kiniksa Pharmaceuticals's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Kiniksa Pharmaceuticals's latest earnings report can be read online.
Read Transcript

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a recorded annual revenue of $270.26 million.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) has a recorded net income of $14.08 million. KNSA has generated -$0.14 earnings per share over the last four quarters.

Kiniksa Pharmaceuticals's earnings are expected to grow from ($0.55) per share to $0.10 per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:KNSA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners